Opendata, web and dolomites

Mofina

Mobile Filovirus Nucleic Acid Test – Sofia ref.: 115848

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Mofina project word cloud

Explore the words cloud of the Mofina project. It provides you a very rough idea of what is the project "Mofina" about.

march    commercial    verification    mobile    format    advantage    laboratory    integration    instrument    april    pan    system    nucleic    detection    proposing    alere    starts    proven    species    care    pcr    kit    designed    venous    bnitm    20    rt    purpose    ready    reg    storage    until    fast    ebola    material    trade    acid    inmi    risk    rapid    cartridge    technologies    manufactured    simultaneously    diagnostics    time    additional    genera    instrumentation    mark    assay    expanded    alone    combining    2015    complete    stand    validation    disposable    central    cartridges    nat    filo    marburgvirus    infrastructure    molecular    workflow    min    logistics    ce    sampling    hiv    point    utilize    platform    safe    screening    infection    capillary    filovirus    sites    reducing    acute    operator    45    realstar    preparation    poc    deg    prototypic    blood    detect    simplify    sensitive    altona    rna    ivd    virus    human    samples    safely   

Project "Mofina" data sheet

The following table provides information about the project.

Coordinator
Department of Health 

Organization address
address: Quarry House, Quarry Hill
city: Leeds
postcode: LS2 7UE
website: www.dh.gov.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.imi.europa.eu/projects-results/project-factsheets/mofina
 Total cost 4˙398˙252 €
 EC max contribution 1˙162˙622 € (26%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Department of Health UK (Leeds) coordinator 332˙460.00
2    ALTONA DIAGNOSTICS GMBH DE (HAMBURG) participant 394˙178.00
3    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN DE (HAMBURG) participant 217˙992.00
4    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 217˙992.00
5    ALERE TECHNOLOGIES GMBH DE (JENA) participant 0.00
6    FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS CH (GENEVE) participant 0.00

Map

 Project objective

We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics platform. The purpose of this project is to utilize existing and proven PCR assay(s) designed for laboratory use and to take advantage of the Alere™ q point of care molecular instrument and cartridge design to simplify Ebola testing so that molecular testing can be expanded to sites beyond which high end laboratory infrastructure is not available while simultaneously greatly reducing infection risk for the test operator. The project aims for the fast development of a point of care Nucleic Acid Test (POC-NAT) system for filovirus specific RNA, from human sample material, especially from blood samples. The POC-NAT system will have the following features: 1. Field proven stand alone, mobile and easy to use instrumentation 2. ready to use cartridge, safely disposable nucleic acid test format with integrated sample preparation 3. assay for specific detection of RNA of all known species from the virus genera Ebola- and Marburgvirus . 4. process duration from sampling to result less than 45 min 5. no additional equipment and no logistics and storage at -20°C needed The POC-NAT is based on two already existing technologies: The instrument platform “Alere™q complete” developed and manufactured by Alere , an instrument for POC diagnostics recently used p.e. for Alere´s HIV-1/2 Detect cartridges, and altona Diagnostics´ RealStar® Filovirus RT-PCR kit 1.0, a commercial central laboratory real-time PCR test. The project partner aim for having the integration of platform and assay as a prototypic system completed until end of March 2015. The verification and validation of the workflow starts April 2015 at altona Diagnostics, BNITM and INMI. The aim of this project phase is to finally CE IVD mark the test system

 Publications

year authors and title journal last update
List of publications.
2015 Chris A Whitehouse, Sina Bavari, Mark D Perkins
United States FDA’s emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future
published pages: 1231-1235, ISSN: 1473-7159, DOI: 10.1586/14737159.2015.1077117
Expert Review of Molecular Diagnostics 15/10 2019-07-24
2015 Mark D Perkins, Mark Kessel
What Ebola tells us about outbreak diagnostic readiness
published pages: 464-469, ISSN: 1087-0156, DOI: 10.1038/nbt.3215
Nature Biotechnology 33/5 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOFINA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOFINA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

NEURONET (2019)

Efficiently Networking European Neurodegeneration Research

Read More